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Abstract Angiotensin II (Ang II) is an important regula-
tor of cardiovascular function in adult vertebrates.
Although its role in regulating the adult system has been
extensively investigated, the cardiovascular response to
Ang II in embryonic vertebrates is relatively unknown. We
investigated the potential of Ang II as a regulator of cardio-
vascular function in embryonic chickens, which lack cen-
tral nervous system control of cardiovascular function
throughout the majority of incubation. The cardiovascular
response to Ang II in embryonic chickens was investigated
over the Wnal 50% of their development. Ang II produced a
dose-dependent increase in arterial pressure on each day of
development studied, and the response increased in inten-
sity as development progressed. The Ang II type-1 receptor
nonspeciWc competitive peptide antagonist [Sar1 ile8] Ang
II blocked the cardiovascular response to subsequent injec-
tions of Ang II on day 21 only. The embryonic pressure
response to Ang II (hypertension only) diVered from that of
adult chickens, in which initial hypotension is followed by
hypertension. The constant level of gene expression for the
Ang II receptor, in conjunction with an increasing pressure
response to the peptide, suggests that two Ang II receptor
subtypes are present during chicken development. Collec-
tively, the data indicate that Ang II plays an important role
in the cardiovascular development of chickens; however, its
role in maintaining basal function requires further study.
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Introduction
In adult mammals, rapid regulation of heart rate and arterial
pressure is achieved largely by variation in sympathetic
nervous outXow (Cowley et al. 1978; Iwamoto and
Rudolph 1981a, b; Persson et al. 1992; Persson 1996; Liu
et al. 2002; Malpas 2002). In mammals and birds, sympa-
thetic function develops gradually over the late embryonic-
fetal period, and is therefore absent or limited during most
of incubation or gestation (Faber et al. 1974; Assali et al.
1978; Thornburg and Morton 1986; Tazawa et al. 1992;
Crossley et al. 2003a,  b). In fetal mammals, several
humoral mechanisms, such as catecholamines and angio-
tensin II (Ang II), are functional before nervous control of
cardiovascular function is present. In the absence of tonic
sympathetic stimulation, these alternative mechanisms
maintain cardiovascular function in fetuses, as illustrated
by the activation of the renin-angiotensin system (RAS)
during bouts of hypoxia in fetal sheep (Lumbers et al.
2001). Embryonic chickens of the White Leghorn strain
lack neural-mediated regulation of heart rate and arterial
pressure throughout the majority of development (Tazawa
et al.  1992; Altimiras and Crossley 2000; Crossley and
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Altimiras 2000; Crossley et al. 2003b). This relative imma-
turity of neural regulation may shift cardiovascular control
to the RAS in embryonic chickens, as seen in fetal mam-
mals (Crossley et al. 2003b).
Several lines of evidence suggest that the RAS is func-
tional early in chicken development. For example, Ang II
behaves as a trophic factor for cardiac and vascular devel-
opment and stimulates erythropoiesis (Aceto and Baker
1990; Baker and Aceto 1990; Topouzis et al. 1992; Gout-
souliak and Rabkin 1998; Le Noble et al. 2000). Further,
Ang II appears to stimulate endothelial nitric oxide (NO)
production in embryonic chickens, as indicated by the Ang
II-induced endothelial-dependent relaxation of aortic rings
(Nishimura et al. 2003). Embryonic chickens also have
high levels of circulating catecholamines (Mulder et al.
2000; Crossley et al. 2003b), which could be caused by
Ang II-stimulated release from adrenal tissue and sympa-
thetic nerve terminals, as in adult vertebrates (Carroll and
Opdyke 1982). In addition, embryonic chickens also pos-
sess both vascular and cardiac Ang II receptors during
development (Le Noble et al. 1991; Topouzis et al. 1992;
Kempf et al. 1999; Kempf and Corvol 2001; Nishimura
2001; Nishimura et al. 2003). These Wndings imply that the
RAS is functional, although the in vivo cardiovascular
response to Ang II is unknown in embryonic chickens.
The purpose of this study was to determine the cardio-
vascular response to Ang II in developing chickens, in
order to assess its potential as a regulator of systemic blood
pressure during ontogeny. To achieve this, we used an inte-
grative approach in a series of experiments during chicken
development. First, we characterized the embryonic physi-
ological response to the hormone. Secondly, we blocked
the Ang II receptor to quantify this peptide’s contribution to
baseline cardiovascular function. Thirdly, we quantiWed the
amount of Ang II in the blood to determine its potential as a
regulatory compound. Fourthly, we quantiWed the Ang II
receptor gene expression that could account for any change
in the cardiovascular response to the hormone over the
second half of development. We tested the hypothesis that
Ang II regulates basal cardiovascular function, becoming
increasingly eVective at raising blood pressure as develop-
ment progresses.
Materials and methods
Source of embryonic chickens
Experiments were conducted in two laboratories. The initial
portion of the study was conducted in the Department of
Ecology and Evolutionary Biology, at the University of
California, Irvine, CA, USA. For these studies, White
Leghorn chicken eggs were purchased from a local hatchery
(AAA Egg Farm, Lakeview, CA, USA). The second por-
tion of the project was conducted in the Department of
Physiology and Pharmacology at Oregon Health and Sci-
ence University, Portland, OR (OHSU), USA. For these
studies, White Leghorn eggs were purchased from Oregon
State University (Corvallis, OR, USA). At both sites, eggs
were placed in incubation at 38 § 0.5°C with a relative
humidity of t60%, and turned automatically every 3 h.
Molecular studies were conducted in the Department of
Biology at the University of North Dakota, Grand Forks,
ND, USA and at OHSU.
Surgical procedures
A saline-Wlled catheter was introduced into a chorioallan-
toic membrane (CAM) artery as previously described
(Crossley and Altimiras 2000). BrieXy, eggs were candled
to locate the artery, and placed in a thermostatically con-
trolled holder at 38 § 0.5°C. Following removal of approx-
imately 1 cm2 of eggshell, the artery was catheterized with
heat-pulled PE-90 tubing Wlled with heparinized 0.9%
saline under a dissection microscope (Wild M3Z). The
catheter was Wxed to the shell with cyanoacrylate glue, and
the egg was placed in an experimental chamber that con-
sisted of a water-jacketed glass container. Eggs were main-
tained at 38 § 0.5°C and supplied with a constant Xow of
water-saturated air during all experiments.
Signal recording and calibration
The arterial catheter from each egg was attached to a pres-
sure transducer (Statham 23) connected to a bridge ampli-
Wer (Gould 5900). Arterial pressure (PA) signals were
stored in a computer (Macintosh G3) using a PowerLab
data acquisition system (PowerLab/8SP, Adinstruments,
Colorado Springs, CO, USA) and PowerLab software
(Chart 5.0). Heart rate (fH) was continuously derived from
the PA signal. In all cases, the reference zero was set at the
top of the covered glass experimental chamber. Egg dis-
tance from the top of the chamber was then measured (cm)
and used to correct for the actual position of the egg below
the top of the chamber, as previously described (Altimiras
and Crossley 2000).
Experimental protocol
The study consisted of four diVerent experimental series.
Each embryo was used in only one series. Series I, II, and
III began with a 1-h post-surgery recovery period to allow
PA and fH to stabilize. Data from embryonic animals that
did not stabilize were not included. Pharmacologic agents
were administered via a T connector in the arterial catheter
line. Each drug injection was followed by a saline Xush thatJ Comp Physiol B (2010) 180:1057–1065 1059
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was twice the volume of the drug mixture. Total injection
volumes were <5% of the total blood volume, based on
prior quantiWcations (RomanoV 1960, 1967). The Xush vol-
ume had no signiWcant eVect on cardiovascular function, as
previously reported in embryonic chickens (Altimiras and
Crossley 2000). Blood samples (Series III) were also taken
from the T connector in the arterial line. For all experimen-
tal series, 20-day-old embryonic chickens were deWned as
internally pipped eggs (rupture of the air-cell), veriWed by
candling, and 21-day-old embryonic chickens were deWned
as embryos that were externally pipped (rupture of the egg-
shell). Series I, II, and III experiments were conducted on
embryos at days 13, 17, 19, 20, and 21 of incubation, with a
total of 170 embryonic chickens studied over the course of
the project.
In Series I experiments, mean arterial pressure (Pmean)
and  fH were measured during serial injections of native
chicken Ang II (Bachem), given in increasing dosages at
100, 250, 500, 1,000, and 2,000 ng/kg to embryonic chick-
ens on each of the Wve studied days. This dosage range was
selected to mirror prior work in adult chickens (Nakamura
et al. 1982). In all cases, the embryonic mass, which was
used to determine the drug dosage, was estimated based on
published mass data (RomanoV 1960, 1967). Between each
injection, Pmean and fH were allowed to return to preinjec-
tion values for 30 min before the next injection was given.
In a separate group of embryonic chickens, the response to
a single injection of Ang II (1,000 ng/kg) was determined
on the designated days, to demonstrate the lack of tachy-
phylaxis during the dose–response study.
In Series II experiments, the role of systemic Ang II in
maintaining basal Pmean and fH was assessed by blocking
the Ang II receptor with the nonspeciWc competitive pep-
tide antagonist [Sar1 ile8] Ang II (Sigma-Aldrich; 4,000 ng/
kg). This peptide was selected based on prior studies dem-
onstrating that it completely eliminated or dramatically
attenuated the cardiovascular response to Ang II in adult
chickens (Nakamura et al. 1982; Nishimura et al. 1982).
The eVectiveness of this antagonist was determined by
comparing the response to a single injection of Ang II
(1,000 ng/kg) 30 min after the blockade to the response of a
separate group treated with Ang II (1,000 ng/kg) only. [Sar1
ile8] Ang II was previously shown to eVectively block the
Ang II type-1 receptor for 60–120 min after injection
(Regoli et al. 1974; Fluharty and Reagan 1989).
In the Series III experiments, sequential blood samples
(four samples of 100 l each) were collected from each
instrumented embryo following a 1-h control period. All
samples were mixed with 5 L of a 15% EGTA solution.
The initial sample volume from all age groups represented
less than 5% of the embryonic blood volume, based on pub-
lished values (RomanoV 1960, 1967). This is well below
the 16–21% blood volume reduction needed to induce a
cardiovascular response in some adult birds (Ploucha and
Fink 1986) and is similar to that taken from adult birds to
quantify Ang I (Nishimura et al. 1981b). These samples
were immediately centrifuged at 10,000g for 10 min to sep-
arate the plasma. Plasma Ang II concentrations in each
sample volume were determined by radioimmunoassay
(Peninsula Laboratories) kit RIK 7002, as previously
described (Giraud et al. 2005). At the completion of these
studies, embryonic chickens were euthanized with an over-
dose of pentobarbital and KCl.
In the Series IV experiments, six embryonic chickens on
each day of incubation (13, 17, 19, and 20) were used for
collection of cardiac and CAM tissue, following euthanasia
with an overdose of pentobarbital. These tissues were used
for extraction and measurement of angiotensin receptor
messenger RNA levels using quantitative real-time PCR as
described in Rhen et al. (2007). Flash-frozen tissues were
homogenized, and total RNA was extracted using an RNeasy
midi kit (Qiagen). Total RNA concentration was deter-
mined using a Nanodrop spectrophotometer (Nanodrop
Technologies, Wilmington, DE, USA). An aliquot of total
mRNA from each sample was run on a formaldehyde-
agarose gel to determine extracted RNA quality as indicated
by discrete 18S and 28S rRNA bands. Total RNA (400 ng)
was reverse-transcribed in a 20 l reaction, using an iScript
cDNA Synthesis kit containing a blend of oligo dT and
random hexamer primers (BioRad, Hercules, CA, USA).
The following method was used to amplify speciWc PCR
products from the cDNA pool: primers for the chicken Ang
II receptor were designed using the Primer Express v2 (ABI
Prism) software, based on the existing Ang II receptor
sequence for the chicken (forward 679 5 TGG CCA TAG
TGC ATC CAG TG 3 reverse 729 5 CAA CAA ACA
TGG TAC GTC GGA 3) (Kempf et al. 1996, Accession #
NM 205157). Primers for the 18S rRNA were based on the
existing sequence for the mouse (forward 1,275, 5 GAC
ACG GAC AGG ATT GAC AGA TTG ATA G 3 and
reverse 1,403, 5 GTT AGC CCA GAG TCT CGT TCG
TT 3, Accession # NR 003278). Sequence alignment anal-
ysis revealed a single base diVerence in these primers
between the mouse and chicken 18S rRNA (van Tuinen
et al. 2000, Accession # AF 173612). These primers were
used to measure the amount of Ang II receptor mRNA and
18S rRNA in each sample, using a QuantiTect SYBR
Green PCR Kit and an Applied Biosystems 7300 Real Time
PCR system, following standard methods described in
Rhen et al. (2007). A serial dilution of the puriWed initial
PCR product was used to produce a standard curve with a
7-log order range starting with 5 £ 106 attograms (ag)/tube.
These standard curves were used to estimate the amount of
mRNA (or, more precisely, cDNA synthesized from the
mRNA) per 5 ng of total RNA extracted from the tissue. In
preliminary studies, these PCR products were sequenced to1060 J Comp Physiol B (2010) 180:1057–1065
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verify that the product was homologous to the region of the
chicken Ang II receptor cDNA and the mouse 18S rRNA
used to design the primers.
Statistical analysis
A one-way ANOVA (repeated measures design and an
LSD post hoc comparison) was used to assess the response
to each Ang II dose when compared with control values, as
well as the dose-dependent diVerences within each age
group studied (Statistica V5.1). This method was also used
to determine the response to serial blood sampling on
plasma Ang II concentrations. A one-way ANOVA was
used to assess diVerences in plasma Ang II levels between
age groups. An unpaired t test was used to assess signiWcant
diVerences in the Pmean and fH responses to 1,000 ng/kg
Ang II injected during the dose–response experiments,
compared to the single injection of this dose within each
age group only. A paired t test was used to determine statis-
tical diVerences in Pmean and fH following the injection of
the Ang II receptor-blocking agent [Sar1 ile8] Ang II within
each age group. A one-way ANOVA on the arcsine trans-
formed percentage change in Pmean and fH for each dosage
of Ang II was used to assess statistical diVerences in the
response between age groups. A one-way ANOVA was
also used to determine statistical diVerences in Pmean and fH
following an Ang II injection (1,000 ng/kg) after treatment
with the blocking agent [Sar1 ile8] Ang II, compared to a
separate group of embryonic chickens treated with
1,000 ng/kg Ang II, within each age group studied.
Gene expression patterns were compared using a one-way
ANOVA with sampling day as the independent variable
and threshold cycle (Ct value) as the dependent variable.
The Ct values for 18S rRNA were used as a covariate to
control for potential variation in the quality of input RNA
as well as variation in the eYciency of the reverse tran-
scription reaction.
All data are presented as mean § SE. The total number
of embryos used on speciWc days of development for each
experimental series is presented in Tables 1, 2, and 3. For
all statistical tests, a p value of <0.05 was considered
signiWcant.
Results
Control values for Pmean and fH (Table 1) were similar to
those previously reported for embryonic White Leghorn
chickens (Tazawa et al. 1992; Crossley and Altimiras
2000). During each dose–response study, the control values
for Pmean did not change signiWcantly between injections at
Table 1 Baseline Pmean and fH for embryonic White Leghorn chickens under control conditions and the Pmean (kPa) within each embryonic age
in response to either increasing doses of Ang II or a single injection of 1,000 ng/kg (1,000 s) in a separate group of chickens
DiVerent letters between pressure responses to the increasing doses of Ang II indicate signiWcant (p < 0.05) diVerences in the response intensity
within an age group. All Pmean were signiWcant (p < 0.05) unless noted by NS. The data are presented as mean § SE. The number of embryos
treated with a single injection of Ang II is indicated in parenthesis
Age nP mean fH (min¡1) Pmean (kPa) Ang II Dose (ng/kg)
100 250 500 1,000 2,000 1,000 s
13 6 (7) 0.78 § 0.05 239 § 30 . 1 2 a 0.21ab 0.26bc 0.31c 0.41d 0.29c
17 8 (8) 1.94 § 0.05 259 § 30 . 2 1 a 0.30a 0.46b 0.74c 0.89c 0.85c
19 8 (10) 2.31 § 0.08 250 § 30 . 2 3 NS 0.44a 0.61a 0.99b 1.20b 1.08b
20 7 (6) 2.75 § 0.07 268 § 40 . 6 2 a 0.86a 0.83a 1.59b 1.69b 1.32b
21 6 (6) 2.85 § 0.10 287 § 40 . 4 3 a 0.96b 1.14b 1.69c 1.64c 1.56c
Table 2 Change in Pmean and fH following a cumulative dose of [Sar1
ile8] Ang II (4,000 ng/kg)
Data are presented as the mean § SE
* A signiWcant (p < 0.05) change from control Pmean values
Day n Pmean (kPa) fH (min¡1)
13 6 0.16 § 0.02 4 § 4
17 6 0.37 § 0.07 ¡0.2 § 1
19 6 0.40 § 0.06* 3 § 4
20 10 0.34 § 0.05* 8 § 3
21 6 0.26 § 0.09 11 § 5
Table 3 Ang II plasma concentrations (pg ml¡1) in White Leghorn
chicken embryos following four sequential blood samples of 100 l
each
Data are presented as a mean § SE. Like letters for each sample
indicate similar plasma Ang II concentrations across the age groups
sampled
*S i g n i Wcant (p < 0.05) concentration diVerences between blood
samples for a given age group
Day n 1st sample 2nd sample 3rd sample 4th sample
13 7 170 § 23ab 157 § 13ab 140 § 11a 176 § 30a
17 9 176 § 19a 194 § 15a 188 § 18b 181 § 23a
19 12 115 § 11c 111 § 10bc 113 § 10a 101 § 17b
20 6 123 § 17bc 100 § 22c 139 § 12a 150 § 20ab
21 6 209 § 47a 151 § 21ac*1 4 6 § 11ab*1 6 0 § 29a*J Comp Physiol B (2010) 180:1057–1065 1061
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any stage of development. The general response to Ang II,
regardless of dose, was a rapid rise in blood pressure fol-
lowed by a return to control levels (Fig. 1a). Unlike Pmean,
Ang II produced inconsistent fH changes on days 19 and 21
only, with a bradycardic response to 250 ng/kg on both
days, and a bradycardic response to 500 and 2,000 ng/kg on
day 21 only (Fig. 2b).
Series I
All doses of Ang II increased Pmean, with the exception of
the 100 ng/kg dose injected on day 19 (Table 1, Fig. 2a).
The intensity of the pressure response increased in a
dose-dependent manner in all age groups, with the increase
ranging from 11 to 66% (Table 1). Select doses of Ang II
caused signiWcant bradycardia on days 19 (250 ng/kg) and
21 (250, 500, and 2,000 ng/kg) (Fig. 2b). The 1,000 ng/kg
dose of Ang II elicited the maximal Pmean response on all
days studied, except day 13, which increased further with
the 2,000 ng/kg dose (Table 1). An age comparison of the
maximal change in Pmean induced by an injection of Ang II
revealed a signiWcant (p < 0.05) change in the hypertensive
response with age, from a 31% increase on day 13 to a 66%
increase on day 21 (Fig. 2a).
In an eVort to ensure the absence of tachyphylaxis to
Ang II during the dose–response series, the Pmean response
to Ang II (1,000 ng/kg) given as a single injection was
compared to the increase when Ang II was injected during
the dose–response series. This comparison revealed no
Fig. 1 Representative traces from two diVerent 21-day-old embryonic
chickens. These traces illustrate the arterial pressure (PA) and heart
rate (fH) response to an injection of a Ang II (1,000 ng/kg) alone, and
b after pretreatment with [Sar1 ile8] Ang II (4,000 ng/kg). For each
trace, the arrow indicates the point of Ang II (1,000 ng/kg) injection.
The bracket indicates a period of 5 min
A
B
Fig. 2 The change in Pmean (a) and fH (b) in response to increasing
concentrations of Ang II injected into embryonic chickens on day
13(Wlled diamonds), 17 (Wlled triangle), 19 (open square), 20 (open tri-
angle), and 21 (Wlled circle). DiVerent letters between the incubation
age groups represent signiWcant diVerences in the degree of change in
response to each dose. Responses that were similar are bracketed. A
single dollar symbol signiWes that the day-21 response did not diVer
from that of days 13 and 17. Double dollar symbol signiWes that the
response on day 20 did not diVer from that of day 13. An asterisk
indicates a signiWcant reduction in fH following an injection of Ang II
on days 19 and 21 only. The data are presented as mean § SE. The
Pmean response was signiWcant on all days of development except for
the lowest dose, on day 19. See Table 2
A
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diVerence between the two protocols in all age groups
studied (Table 1).
Series II
Pretreatment with the Ang II type-1 receptor nonspeciWc
competitive peptide antagonist [Sar1 ile8] Ang II (4,000
ng/kg) signiWcantly elevated Pmean on days 19 and 20
(Table 2). This blocking agent reduced the intensity of Ang
II-induced hypertension (1,000 ng/kg) on day 21 only
(Fig. 3). Pretreatment with [Sar1 ile8] Ang II (4,000 ng/kg)
did not alter fH (Table 2).
Series III
Plasma concentrations of Ang II were high throughout the
developmental period studied, averaging 160 pg ml¡1
(Fig. 4). Plasma Ang II levels signiWcantly dropped on day
19, but returned to pre-day 19 levels by day 21 (Fig. 4).
Multiple acute blood samples had no impact on plasma Ang
II concentrations, with the exception of those taken on day
21, when Ang II concentration decreased (Table 3).
Series IV
The eYciencies of the quantitative PCR reaction for both
the Ang II receptor cDNA and 18S rRNA averaged »85%
during the incubation period studied. The Ang II receptor
mRNA concentrations in the CAM averaged »1,500
ag £ 5n g  R N A ¡1 with a trend toward decreasing at day 20
(Fig. 5a). A similar trend was evident in the embryonic
heart, which averaged 490 ag £ 5n g  R N A ¡1 (Fig. 5b).
Discussion
Ang II caused a dose-dependent hypertension increasing in
intensity during the Wnal days of embryonic maturation.
Fig. 3 The peak change in Pmean following an injection of Ang II
1,000 ng/kg when given as a single injection (open bar), or in a sepa-
rate group following pre-injection with [Sar1 ile8] Ang II 4,000 ng/kg
(Wlled bar). An asterisk indicates a signiWcant (p <0 . 0 5 )  d i Verence in
the pressure response between the two injections on a given day of
incubation. The data are presented as mean § SE
Fig. 4 The control plasma Ang II concentrations in embryonic chick-
ens during the period of development studied. DiVerent letters between
any two incubation age groups indicates a signiWcant (p < 0.05) diVer-
ence in the plasma Ang II concentration between the groups. The data
are presented as mean § SE
Fig. 5 The Ang II mRNA concentration per 5 ng of total RNA in
a whole CAMs, and b hearts from embryonic chickens at 13, 17, 19,
and 20 days of development. The data are presented as mean § SE
A
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Although the physiological response to Ang II increased
with development, the mRNA levels for the Ang II receptor
remained constant in embryonic hearts and CAMs. The
pressure response to Ang II and the high level of endoge-
nous peptide in the blood indicate that Ang II plays an
important role in embryonic chicken cardiovascular devel-
opment. However, the contribution of these elevated Ang II
levels to maintaining basal cardiovascular function is
unclear.
Pharmacological response
The 1,000 ng/kg dose of Ang II maximally increased Pmean
on all days studied, except day 13. At this dose, the inten-
sity of the Pmean change was dependent on embryonic age,
with a distinct increase during the Wnal days of incubation
(Fig. 2a). The mechanisms underlying this increased Ang II
response with age were not directly addressed in this study.
Prior studies comparing early- and late-gestation fetal
sheep demonstrated that kidney Ang II type-1 receptor
mRNA expression and receptor density increase as a func-
tion of ontogeny (Robillard et al. 1995; Butkus et al. 1997).
However, studies using cardiac tissue reported that Ang II
type-1 receptor mRNA expression remained constant dur-
ing the Wnal trimester of sheep ontogeny or decreased from
day 80 to the postnatal period (Margaret et al. 1998; Reini
et al.  2009). Given that this issue is unresolved in fetal
sheep and in our current Wndings, it would be diYcult to
ascribe the physiological pattern demonstrated here in
embryonic chickens to a change in cardiovascular Ang II
type-1 receptor gene expression. The increasing Pmean
response to Ang II could be attributed to a maturing adren-
ergic contribution in embryonic chickens. This suggestion
is based on the previous Wnding that Ang II increases circu-
lating catecholamine levels (both norepinephrine and epi-
nephrine) in adult vertebrates (Carroll and Opdyke 1982).
In addition, in adult chickens, Ang II results in an adrener-
gic-dependent vasoconstriction due to sympathetic nerve
terminal release of catecholamines (Nishimura et al. 1981a,
b; Nakamura et al. 1982; Nishimura et al. 2003). Embry-
onic chicken adrenal tissue also contains Ang II receptors,
which could provide a mechanism for catecholamine
release due to this peptide, similar to the mechanism seen in
adult birds (Nishimura et al. 2003). Finally, the cardiovas-
cular response to tyramine, a compound that causes cate-
cholamine release from postganglionic neurons, increases
in intensity as embryonic development progresses (Cross-
ley 1999; Crossley et al. 2003b). If Ang II causes sympa-
thetic nerve terminal release of catecholamines in the
embryo, as in the adult, then this sympathetic maturation
could explain the Ang II pressure pattern documented in
our study. The increasing response to Ang II could be due
to an increased capacity for this peptide to cause catechol-
amine release from sympathetic terminals and/or adrenal
tissue during chicken development.
Although embryonic chickens exhibited a clear hyper-
tensive response to Ang II, the initial hypotension previ-
ously characterized in adult birds (Nakamura et al. 1982)
was absent throughout development (Fig. 2a). This diVer-
ence could be explained in part by the elevated levels of
endogenous Ang II in the embryonic animal (Fig. 4). In
adult chickens, the two-phase pressure response to Ang II
requires two functioning systems: the nitric oxide pathway
and functional sympathetic nerve terminals (where Ang II
binds, causing a release of catecholamines) (Nishimura
et al.  1981a,  b; Nakamura et al. 1982; Hasegawa et al.
1993; Nishimura et al. 1994). The endothelial-dependent
nitric oxide pathway is functional in isolated aortic rings
taken from 19-day-old chicken embryos (Nishimura et al.
2003). Embryonic chickens, like fetal mammals, exhibited
plasma levels of Ang II (Fig. 4) three to four times higher
than those found in adult birds under normal hydrated states
(Gray and Simon 1985; Kobayashi and Takei 1982). These
elevated levels could saturate the Ang II-induced release of
nitric oxide in embryonic chickens, as previously suggested
by Nishimura et al. (2003), preventing the additional Ang II
injected during this study from producing a drop in pres-
sure. Regardless of the diVerence in adult and embryonic
hypotensive response, the increasing hypertensive response
to the hormone with age, combined with the elevated levels
of the peptide in the blood, suggest that Ang II plays a
role in maintaining cardiovascular function in embryonic
chickens.
Blockade of the Ang II receptor
As noted, embryonic White Leghorn chickens lack neural-
mediated regulation of cardiovascular function throughout
the majority of development (Tazawa et al. 1992; Altimiras
and Crossley 2000; Crossley and Altimiras 2000; Crossley
et al. 2003b). Basal cardiovascular function may instead be
maintained by systemically released hormones such as Ang
II during chicken ontogeny. To verify this, we used the Ang
II receptor-blocking agent [Sar1 ile8] Ang II, an eVective
nonspeciWc competitive peptide antagonist in adult chick-
ens and isolated embryonic vessels (Nakamura et al. 1982;
Kempf and Corvol 2001; Nishimura et al. 2003). However,
the blocking agent had no impact on the embryonic hyper-
tensive response to the peptide until day 21 of development
(Fig. 3). Although the blocking agent was developed for
use in mammalian studies, it is also eVective in adult chick-
ens, despite the 25% amino acid diVerence between the
mammalian and chicken Ang II type-1 receptor (Nishimura
2001).
We can only speculate about the basis for the diVering
blockade capacity in adult versus embryonic chickens.1064 J Comp Physiol B (2010) 180:1057–1065
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DiVerences in the Ang II type-1 receptor are unlikely to be
the cause; we cloned and sequenced the embryonic Ang II
receptor cDNA, which was 99.0% homologous to the adult
sequence (Kempf et al. 1996; Crossley et al., unpublished
data). Although not directly studied in the current work,
multiple Ang II receptor subtypes with diVering functions
have been identiWed in mammals (Chiu et al. 1989), and it
is conceivable that a second Ang II receptor subtype may
account for the persistent Ang II actions following treat-
ment with [Sar1 ile8] Ang II. Two Ang II receptors, types 1
and 2, have been suggested based on blockade studies con-
ducted using isolated embryonic chicken cardiomyocytes
(Bkaily et al. 2005). Further, a predicted Ang II type-2
receptor sequence has been indentiWed in the chicken
genome (Accession #XM 426266). These data, coupled
with our Wndings, indicate that a second receptor subtype is
present in embryonic chickens, which could account for the
persistent Ang II response following treatment with the
blocking agent. Although this argument is plausible, the
contribution of Ang II to resting cardiovascular function in
embryonic chickens remains unclear, due to the limited
blocking capacity of [Sar1 ile8] Ang II in this study.
Ang II mRNA expression patterns
Ang II type-1 receptor mRNA in embryonic hearts and
CAMs remained constant during the period of development
studied, while the physiological response to the peptide
increased (Fig. 5a, b). Protein quantiWcation was not con-
ducted in the current study, but protein concentration may
increase even if mRNA for the receptor is constant. This
could account for the increasing physiological response to
the peptide. If gene expression levels are indicative of the
number of Ang II receptors present in the tissue, then the
maturation of an intracellular signaling mechanism could
account for our Wndings. In addition, the increased pressure
response intensity could be attributed to the development of
the vascular smooth muscle contractile apparatus, as previ-
ously suggested (Le Noble et al. 2000). Both scenarios
would account for the mismatch between the gene expres-
sion for the receptor and the development of the physiolog-
ical response to Ang II in embryonic chickens.
In conclusion, using an integrative approach to investi-
gate the feasibility of Ang II as a cardio-regulatory mecha-
nism, we found evidence that it plays an important role in
cardiovascular development in chickens. We determined
that there is an increasing pressure response to the peptide
with embryonic development. Nevertheless, the contribu-
tion of Ang II in maintaining basal PA and fH in embryonic
chickens remains unclear, due to the limited receptor-
blocking capacity of [Sar1 ile8] Ang II. Our hypothesis that
the PA response to Ang II would increase with development
was conWrmed. However, this increase could not be
attributed to any change in Ang II type-1 receptor gene
expression or to a change in circulating levels of the pep-
tide. The data also suggest that the cardiovascular response
to Ang II must undergo changes during the embryonic
period to resemble changes previously characterized in
adult chickens. We have presented several theories that
would account for these diVerences. Further study is needed
to clarify how the regulatory function of Ang II matures,
and ultimately, to establish its role in maintaining basal
cardiovascular function during development in chickens.
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